Thoma Bravo said Wednesday that it has inked an agreement to acquire Empirix. No financial terms were disclosed. The transaction is expected to close by early November. BMO Capital Markets advised Empirix on this deal. Headquartered in Billerica, Mass., Empirix is a provider of end-to-end network testing, monitoring and analytics solutions.
BILLERICA, Mass.–(BUSINESS WIRE)–Thoma Bravo, LLC, a leading private equity investment firm, announced today that it has signed a definitive agreement to acquire Empirix Inc., the recognized leader in end-to-end network testing, monitoring and analytics solutions. Financial terms were not disclosed.
“Empirix helps service providers, mobile operators and enterprises master complexities within their networks and optimize business performance with real-time intelligence to reduce operational costs, maximize customer retention and grow top-line revenues.
The Empirix customer base consists of top communication service providers, mobile operators, banks, insurance and healthcare companies. The company has achieved significant growth over the past five years, reporting 22 percent year-over-year revenue growth in 2012, partially driven by a significant increase in bookings from global Tier 1 mobile operators.
“Empirix is a clear leader in the field of service assurance and network management,” said Robert Sayle, principal, Thoma Bravo. “We are very excited about this partnership.”
“The company offers a unique ability to analyze customer behaviors by application in real time,” added Seth Boro, partner, Thoma Bravo. “Its products, strategy and leadership have positioned it for success, and we look forward to accelerating that success through organic growth and strategic acquisition opportunities.”
Thoma Bravo has deep experience in the service assurance and network management markets. Recent investments include Network Instruments, InfoVista, Blue Coat Systems, nCircle, SonicWALL, Mentum, Solera Networks, Netronome, and more recently Keynote Systems.
“Empirix has experienced significant growth in the past several years as companies strive to better manage and transform complex communications systems and the business objectives they support,” said John D’Anna, the company’s chief executive officer. “The resources of Thoma Bravo will strengthen our position to meet our customer’s glaring need for next-gen technology, while we rapidly complete our plan to bridge applications and network monitoring for both the enterprise and service provider markets.”
The transaction is expected to be finalized by early November.
BMO Capital Markets acted as financial advisor to Empirix on this transaction.
Empirix is the recognized leader in end-to-end network performance visibility with the unique ability to analyze customer behaviors, by application, in real-time, through an innovative approach to enabling the build-out of the Service Operations Center model. We help service providers, mobile operators, contact centers and businesses master complexities to drive improvements in customer experience and user satisfaction. Through testing, monitoring, analytics and intelligence, Empirix helps companies around the world maximize their technology investments while reducing implementation and customer impact risks. For further information, please visit www.empirix.com.
About Thoma Bravo
Thoma Bravo is a leading private equity investment firm building on a 30+ year history of providing equity and strategic support to experienced management teams and growing companies. The firm applies its own industry consolidation investment strategy and process, which seeks to create value by partnering with a company’s management to improve business operations and make strategic acquisitions that will accelerate growth. Thoma Bravo invests across multiple industries, with a particular focus on application and infrastructure software and financial and business services. The firm currently manages a series of private equity funds representing more than $4 billion of equity commitments. For more information, visit www.thomabravo.com.
Empirix is a trademark of Empirix Inc. in the United States and other countries
Neurotrope said Wednesday that it has completed a $1.08 million private placement. The company sold 1,080,00 shares of its Series A stock at a price of $1 per share to accredited investors. Intuitive Venture Partners served as financial advisor to Neurotrope in the transaction while EDI Financial was the placement agent. Headquartered in Plantation, Florida, Neurotrope is a biopharmaceutical and diagnostics company principally focused on Alzheimer’s Disease.
PLANTATION, Fla., Oct. 9, 2013 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it completed a closing of the sale of 1,080,000 shares of its Series A convertible preferred stock in a private offering to accredited investors, at a price of $1.00 per share, resulting in gross proceeds to Neurotrope of $1,080,000 (before deducting commissions and expenses of the offering). Neurotrope had previously sold 21,920,000 shares of its Series A convertible preferred stock in three prior closings of this private placement in February, May and August 2013, at the same purchase price per share, for aggregate gross proceeds of $21,920,000 (before deducting commissions and expenses of the offering). The total gross amount raised by Neurotrope in its Series A convertible preferred offering has been $23,000,000.
Intuitive Venture Partners, LLC, was the exclusive financial advisor to Neurotrope. EDI Financial, Inc. was the exclusive placement agent for the best efforts private placement offering, and Gottbetter Capital Markets, LLC, was a sub-agent.
The Company’s Chief Executive Officer, Dr. Jim New, said, “This additional support from both established and new investors in Neurotrope is very much appreciated. These incremental funds will be allocated to accelerating some of our key product development programs.”
The Company intends to use net proceeds of the offering, principally for pre-clinical and clinical research costs, as well as to pay royalties, patent expenses and general and administrative expenses.
The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under, or exemption from registration under, such Act.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer’s Disease and a drug candidate called bryostatin for the treatment of Alzheimer’s Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute (“BRNI”) and its affiliates, for therapeutic or diagnostic applications for Alzheimer’s Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer’s Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer’s Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the “blood-brain-barrier,” and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Please visit www.neurotropebioscience.com for further information.